Get the Stockscreener App
8.54
0.12%
-0.01
Chimerix Inc stock is traded at $8.54, with a volume of 755.34K.
It is down -0.12% in the last 24 hours and up +0.83% over the past month.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$8.55
Open:
$8.55
24h Volume:
755.34K
Relative Volume:
0.20
Market Cap:
$801.08M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
-9.1828
EPS:
-0.93
Net Cash Flow:
$-69.18M
1W Performance:
+0.12%
1M Performance:
+0.83%
6M Performance:
+879.02%
1Y Performance:
+844.69%
1-Day Range:
$8.54
$8.55
1-Week Range:
$8.52
$8.55
52-Week Range:
$0.75
$8.55
Chimerix Inc Stock (CMRX) Company Profile
Name
Chimerix Inc
Sector
Industry
Phone
919.806.1074
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Compare CMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.54 | 801.08M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | Robert W. Baird | Outperform |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Apr-29-21 | Initiated | Maxim Group | Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-31-21 | Initiated | Jefferies | Buy |
| Mar-31-21 | Initiated | Wedbush | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-02-18 | Initiated | H.C. Wainwright | Buy |
| Aug-09-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-23-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-22-16 | Downgrade | Citigroup | Buy → Neutral |
| Dec-29-15 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-15 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| Dec-28-15 | Reiterated | Piper Jaffray | Overweight |
| Dec-17-15 | Initiated | UBS | Buy |
| Oct-05-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-03-15 | Initiated | Citigroup | Buy |
| Aug-18-15 | Initiated | FBR Capital | Outperform |
| Aug-06-15 | Reiterated | Brean Capital | Buy |
| May-11-15 | Reiterated | Brean Capital | Buy |
| Mar-04-15 | Initiated | Barclays | Overweight |
| Feb-12-15 | Reiterated | Stifel | Buy |
| Dec-31-14 | Reiterated | Brean Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
View All
Chimerix Inc Stock (CMRX) Latest News
Chimerix stock soars to 52-week high, hits $8.54 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.54 - Investing.com
Unlocking Investment Potential Discover the Power of Magical Signals Bullish Signal - AInvest
Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
Jazz Pharmaceuticals, Chimerix HSR waiting period expired on March 31 - MLex
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
11 Best Performing NASDAQ Stocks So Far in 2025 - Insider Monkey
Exploring US High Growth Tech Stocks In March 2025 - simplywall.st
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo Finance
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Chimerix Reports 2024 Losses Amid Acquisition News - TipRanks
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Chimerix Reports Earnings as $935M Jazz Buyout and FDA Drug Review Advance - StockTitan
Investment Analysts’ Recent Ratings Updates for Chimerix (CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $8.47 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.47 - Investing.com India
Ireland: Jazz adds to oncology pipeline with Chimerix - Investors in Healthcare
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Victoria Advocate
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - Financial Content
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire
Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
Chimerix Expands Team with Strategic New Hire, Offers 70K Share Options Package - StockTitan
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair - Bluefield Daily Telegraph
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - GlobeNewswire
HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix Inc Stock (CMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):